Scarica l'app Stockscreener
16.23
1.18%
0.19
Dopo l'orario di chiusura:
16.21
-0.02
-0.12%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$16.04
Aprire:
$15.902
Volume 24 ore:
8.20M
Relative Volume:
0.80
Capitalizzazione di mercato:
$18.64B
Reddito:
$14.57B
Utile/perdita netta:
$-296.50M
Rapporto P/E:
-62.66
EPS:
-0.259
Flusso di cassa netto:
$1.64B
1 W Prestazione:
-1.22%
1M Prestazione:
-0.49%
6M Prestazione:
+2.92%
1 anno Prestazione:
+51.82%
Intervallo 1D:
$15.88
$16.27
Intervallo di 1 settimana:
$15.88
$16.71
Portata 52W:
$9.425
$18.39
Viatris Inc Stock (VTRS) Company Profile
Nome
Viatris Inc
Settore
Telefono
(724) 514-1465
Indirizzo
1000 MYLAN BOULEVARD, CANONSBURG
Compare VTRS vs TAK, TEVA, HLN, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
16.23 | 18.49B | 14.57B | -296.50M | 1.64B | -0.259 |
TAK
Takeda Pharmaceutical Co Adr
|
17.63 | 55.60B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.77 | 42.81B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.70 | 43.16B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
73.79 | 30.39B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
499.73 | 21.95B | 3.17B | 1.29B | 1.01B | 27.09 |
Viatris Inc Stock (VTRS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-09 | Aggiornamento | UBS | Neutral → Buy |
| 2026-01-16 | Aggiornamento | Argus | Hold → Buy |
| 2025-12-09 | Iniziato | Barclays | Overweight |
| 2025-10-15 | Iniziato | Truist | Buy |
| 2025-06-06 | Iniziato | Goldman | Neutral |
| 2024-07-19 | Ripresa | Jefferies | Buy |
| 2023-10-23 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-06-23 | Downgrade | Barclays | Equal Weight → Underweight |
| 2023-04-24 | Downgrade | Barclays | Overweight → Equal Weight |
| 2023-02-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-27 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-11-10 | Aggiornamento | UBS | Sell → Neutral |
| 2022-11-08 | Aggiornamento | Piper Sandler | Underweight → Neutral |
| 2022-10-21 | Ripresa | Jefferies | Hold |
| 2022-06-14 | Iniziato | UBS | Sell |
| 2022-05-10 | Downgrade | Piper Sandler | Neutral → Underweight |
| 2022-03-01 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-03-01 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2021-06-15 | Iniziato | Citigroup | Neutral |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2021-03-08 | Downgrade | Goldman | Buy → Neutral |
| 2021-03-02 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-02-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2021-01-05 | Iniziato | Argus | Hold |
| 2020-12-14 | Iniziato | Bernstein | Mkt Perform |
Mostra tutto
Viatris Inc Borsa (VTRS) Ultime notizie
5 Must-Read Analyst Questions From Viatris’s Q2 Earnings Call - Yahoo Finance
Viatris Inc. stock rises Friday, outperforms market - MarketWatch
Viatris Inc (VTRS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Viatris Inc. (VTRS) Stock Price, News, Quote & History - Yahoo! Finance Canada
Viatris (VTRS) is Selling Tyrvaya, but Could Harrow (HROW) Turn it Into a Growth Engine? - Yahoo Finance
Viatris (VTRS) Q1 2026 Earnings Call Transcript - Fortune
Viatris (VTRS) Q4 2025 Earnings Call Transcript - Fortune
Viatris Inc. stock falls Wednesday, underperforms market - MarketWatch
Davis Selected Advisers (VTRS) discloses 75.2M-share, 6.5% stake in Viatris Inc - Stock Titan
ETFs Investing in Viatris, Inc. Stocks - TradingView
TBPH Meets Q2 Earnings Estimates, to be Acquired by Zymeworks - TradingView
Viatris (VTRS) Stock Trades At A Discount To Sales Despite A 76% Run - Sahm
Theravance Biopharma Q2 2026: Viatris collaboration revenue $20.7M; net loss $5.9M; $388M cash - TradingView
Viatris Inc. (VTRS) Stock Analysis: Unveiling a 12.6% Potential Upside Amidst Strong Cash Flow - DirectorsTalk Interviews
Why Viatris (VTRS) Is Down 6.4% After Boosting Guidance And Completing A $1.15 Billion Buyback - simplywall.st
Viatris (VTRS) Is Down 6.4% After Raising 2026 Guidance And Completing Major Buyback Program - Yahoo Finance
Viatris (VTRS) Stock May Be Below Fair Value Despite FDA Patch Approval - Yahoo Finance
Viatris (VTRS) Stock Sees Modest Fair Value Lift After Q1 Results And Pipeline Progress - Yahoo Finance
Viatris Inc. (VTRS) Stock Forecasts - Yahoo! Finance Canada
Viatris (VTRS) Stock Looks Stuck Between Higher Guidance And Wider Losses - Sahm
Viatris Inc. (US92556V1061.SG) Stock Price, News, Quote & History - Yahoo! Finance Canada
Viatris Inc. Stock Sheds 7.7%, Underperforms Market - webull.com
Viatris Earnings: Good Performance in Key Regions and Outlook Increase Make for a Solid Quarter - Morningstar
Harrow Enters Agreement to Acquire Tyrvaya Dry Eye Treatment From Viatris Inc. - VisionMonday.com
Viatris Inc. Stock 12‑Month Price Target Raised to $18.71, Implies 6% Upside - TradingView
Viatris Inc (VTRS) (Q2 2026) Earnings Call Highlights: Strong Growth and Raised Guidance Amid ... - Yahoo Finance
Viatris Inc (VTRS) Shares Fall 7.6% -- GF Value Says Still Overv - GuruFocus
Viatris Inc. stock falls Thursday, underperforms market - MarketWatch
Viatris Inc Q2 2026: Revenue $3.76B, EPS $(0.10) — 10-Q Summary - TradingView
Viatris (NASDAQ: VTRS) swings to H1 2026 profit as revenue tops $7.27B - Stock Titan
Tranche Update on Viatris Inc.'s Equity Buyback Plan announced on February 28, 2022. - marketscreener.com
Viatris Q2 2026 slides: strong beat, raised outlook, H2 headwinds - Investing.com
Viatris Q2 2026 slides: strong results lift guidance amid H2 headwinds - Investing.com
Viatris Sharpens Focus with Divestiture, Hikes 2026 Outlook - TradingView
Viatris Looks to New Launches, Pipeline Progression, and Cost Savings for Long-Term Growth - Morningstar
Viatris Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:VTRS) 2026-08-06 - Seeking Alpha
Viatris stock hits 52-week high at 18.27 USD - Investing.com
Viatris Q2 2026 slides: strong beat drives guidance raise - Investing.com
FMR LLC discloses 8.3% Viatris Inc (VTRS) ownership, over 96M shares - Stock Titan
Earnings call transcript: Viatris tops Q2 2026 estimates, lifts outlook - Investing.com
Viatris Announces Quarterly Dividend - marketscreener.com
Viatris Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Compared to Estimates, Viatris (VTRS) Q2 Earnings: A Look at Key Metrics - Yahoo Finance
Viatris Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
VIATRIS INC (VTRS.VI) Q2 FY2026 earnings call transcript - Yahoo Finance
Viatris (VTRS) Beats Q2 Earnings and Revenue Estimates - Yahoo Finance
Viatris' Q2 Adjusted Earnings, Revenue Rise; Lifts 2026 Guidance - marketscreener.com
(VTRS) Viatris Expects 2026 Revenue Range $14.55B$14.95B, vs. FactSet Est of $14.79B - marketscreener.com
(VTRS) Viatris Expects 2026 Adjusted EPS Range $2.45$2.59, vs. FactSet Est of $2.45 - marketscreener.com
Viatris raises annual profit forecast on branded drug strength - marketscreener.com
Viatris (NASDAQ:VTRS) Posts Better-Than-Expected Sales In Q2 CY2026 - Yahoo Finance
Viatris Inc Azioni (VTRS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.31%
1.26%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):